2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1475-1484

  Besse, Benjamin ^a,n   Adjei, A ^b   Baas, P ^c   Meldgaard, P ^d   Nicolson, M ^e   Paz Ares, L ^f   Reck, M ^g   Smit, E F ^h   Syrigos, Konstantinos ⁱ   Stahel, Rolf ^j   Felip, E ^k   Peters, S ^l   Kerr, Keith ^m   Vansteenkiste, Johan ^o   Eberhardt, Wilfried ^p   Edelman, Martin ^q   Mok, Tony ^r   O'Byrne, Ken ^s   Novello, Silvia ^t   Bubendorf, Lukas ^u   Marchetti, Antonio ^v   Baas, Paul ^c   Reck, Martin ^g   Meldgaard, Peter ^d   Adjei, Alex ^b   Nicolson, Marianne ^e   Crinò, Lucio ^w   Van Schil, Paul ^x   Senan, Suresh ^h   Faivre Finn, Corinne ^y   Rocco, Gaetano ^z   Veronesi, Giulia ^aa   Douillard, Jean Yves ^ab   Lim, Eric ^ac   Dooms, Christophe ^o   Weder, Walter ^j   De Ruysscher, Dirk ^o   Le Pechoux, Cecile ^a   De Leyn, Paul ^o   Westeel, Virginie ^ad   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g KRANKENHAUS GROSSHANSDORF   (Germany)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ SOTIRIA GENERAL HOSPITAL   (Greece)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^m UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁿ Universite Paris Sud   (France)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p UNIVERSITY HOSPITAL ESSEN   (Germany)

^q UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^r CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^s ST JAMES S HOSPITAL   (Ireland)

^t SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^u UNIVERSITY HOSPITAL BASEL   (Switzerland)

^v UNIVERSITY OF CHIETI   (Italy)

^w SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^x ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^y CHRISTIE HOSPITAL   (United Kingdom)

^z NATIONAL CANCER INSTITUTE   (Italy)

^aa EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^ab Integrated Centers of Oncology R Gauducheau   (France)

^ac ROYAL BROMPTON HOSPITAL   (United Kingdom)

^ad UNIVERSITÉ DE FRANCHE COMTÉ   (France)

more..

Author keywords

Consensus; Esmo; Further lines; Non small cell lung cancer

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; CRIZOTINIB; DABRAFENIB; DENOSUMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; SORAFENIB; TAXANE DERIVATIVE; TRASTUZUMAB; VANDETANIB; VINBLASTINE; ZOLEDRONIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CONSENSUS DEVELOPMENT; DRUG EFFICACY; DRUG RECHALLENGE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUTATION; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY HEALTH CARE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGE; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CONSENSUS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PROCEDURES; STANDARDS; UTILIZATION;

AGE FACTORS; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CONSENSUS; DRUG SUBSTITUTION; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; NEOADJUVANT THERAPY;

EID: 84905195418     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu123     Document Type: Article

References (68)

1. Felip E, Gridelli C, Baas P et al. Metastatic non-small cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011; 22: 1973-80.
2. Stahel R, Thatcher N, Fruh M et al. 1st ESMO consensus conference in lung cancer; Lugano 2010: Small cell lung cancer. Ann Oncol 2011; 22: 1973-80.
3. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-44.
4. Group NM-AC. Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. J. Clin. Oncol. 2008; 26(28):4617-4625.
5. Group TELCVIS. Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer. J. Natl. Cancer Inst. 1999; 91(1):66-72.
6. Fidias PM, Dakhil SR, Lyss AP et al. Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2009; 27(4):591-598.
7. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J.Clin.Oncol. 2004; 22(19):3852-3859.
8. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis. JNCI J. Natl. Cancer Inst. 2007; 99(11):847-857.
9. Goffin J, Lacchetti C, Ellis PM et al. First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer. J. Thorac. Oncol. 2010; 5(2):260-274.
10. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J.Clin.Oncol. 2008; 26(21):3543-3551.
11. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N.Engl.J.Med. 2002; 346(2):92-98.
12. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced nonsmall-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 2003; 21(16):3016-3024.
13. Smith IE, O'Brien ME, Talbot DC et al. Duration of chemotherapy in advanced nonsmall-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2001; 19(5):1336- 1343.
14. Von Plessen C, Bergman B, Andresen O et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-smallcell lung cancer. Br. J. Cancer 2006; 95(8):966-973.
15. Park JO, Kim S-W, Ahn JS et al. Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2007; 25(33):5233-5239.
16. Lima JP da SN, Santos LV dos, Sasse EC, Sasse AD. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with metaanalysis. Eur. J. Cancer 2009; 45(4):601-607.
17. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. J. Clin. Oncol. 2009; 27(20):3277-3283.
18. Soria JC, Mauguen A, Reck M et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2013; 24(1):20-30.
19. Sandler A, Gray R, Perry MC et al. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2006; 355(24):2542-2550.
20. Reck M, Von Pawel J, Zatloukal P et al. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL. J. Clin. Oncol. 2009; 27(8):1227-1234.
21. Reck M, Pawel J von, Zatloukal P et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann. Oncol. 2010; 21(9):1804-1809.
22. Herbst RS, Ansari R, Bustin F et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. The Lancet; 377(9780):1846-1854.
23. Reck M, Kaiser R, Mellemgaard A et al. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. ASCO Meet. Abstr. 2013; 31(18_suppl):LBA8011.
24. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. The Lancet 24; 374(9699):1432-1440.
25. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010; 11(6):521-529.
26. Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012; 13(3):247-255.
27. Sacher AG, Le LW, Leighl NB, Coate LE. Elderly Patients with Advanced NSCLC in Phase III Clinical Trials. J. Thorac. Oncol. 2013; 8(3):366-368.
28. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. J. Natl. Cancer Inst. 2003; 95(5):362-372.
29. Quoix E, Zalcman G, Oster J-P et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-smallcell lung cancer: IFCT-0501 randomised, phase 3 trial. The Lancet 17; 378(9796):1079- 1088.
30. Smit EF, Burgers SA, Biesma B et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J.Clin.Oncol. 2009; 27(12):2038-2045.
31. Ardizzoni A, Tiseo M, Boni L et al. Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial. J. Clin. Oncol. 2012; 30(36):4501-4507.
32. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2005; 353(2):123-132.
33. Paz-Ares L, Hirsh V, Zhang L et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III, randomized, double-blind, placebo-controlled mission trial. Ann Oncol 2012:ixe23.
34. Girard N, Jacoulet P, Gainet M et al. Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice. J. Thorac. Oncol. 2009; 4(12):1544-1549.
35. Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial-The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 2003; 21(16):3150-3157.
36. Scagliotti GV, Hirsh V, Siena S et al. Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid. J. Thorac. Oncol. 2012; 7(12):1823-1829.
37. Gridelli C, Ardizzoni A, Chevalier TL et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann. Oncol. 2004; 15(3):419-426.
38. Langer CJ, O'Byrne KJ, Socinski MA et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced nonsmall cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2008; 3(6):623-630.
39. Morabito A, Gebbia V, Cinieri S et al. Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) 2: CAPPA-2 study. ASCO Meet. Abstr. 2013; 31(15_suppl):8066.
40. Zukin M, Barrios CH, Pereira JR et al. Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2. J. Clin. Oncol. 2013. doi:10.1200/JCO.2012.48.1911.
41. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J.Clin.Oncol. 2000; 18(10):2095-2103.
42. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J.Clin.Oncol. 2004; 22(9):1589-1597.
43. Ciuleanu T, Stelmakh L, Cicenas S et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012; 13(3):300-308.
44. Lee DH, Park K, Kim JH et al. Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy. Clin. Cancer Res. 2010; 16(4):1307-1314.
45. Garassino MC, Martelli O, Broggini M et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013; 14(10):981-988.
46. Rosell R, Moran T, Queralt C et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. N. Engl. J. Med. 2009; 361(10):958-967.
47. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N. Engl. J. Med. 2009; 361(10):947-957.
48. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11(2):121-128.
49. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-246.
50. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. N. Engl. J. Med. 2010; 362(25):2380-2388.
51. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-742.
52. Welsh JW, Komaki R, Amini A et al. Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2013; 31(7):895-902.
53. Lee CK, Brown C, Gralla RJ et al. Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. J. Natl. Cancer Inst. 2013; 105(9):595-605.
54. Cadranel J, Mauguen A, Faller M et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2012; 7(10):1490-1502.
55. Nishie K, Kawaguchi T, Tamiya A et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease. J. Thorac. Oncol. 2012; 7(11):1722-1727.
56. Chaft JE, Oxnard GR, Sima CS et al. Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design. Clin. Cancer Res. 2011; 17(19):6298-6303.
57. Watanabe S, Tanaka J, Ota T et al. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer 2011; 11(1):1.
58. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012; 13(5):528-538.
59. Shaw AT, Kim D-W, Nakagawa K et al. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. N. Engl. J. Med. 2013; 368(25):2385-2394.
60. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease. J. Clin. Oncol. 2013; 31(8):1070-1080.
61. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Sci. Transl. Med. 2011; 3(75):75ra26-75ra26.
62. Arcila ME, Oxnard GR, Nafa K et al. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay. Clin. Cancer Res. 2011; 17(5):1169-1180.
63. Yu HA, Arcila ME, Rekhtman N et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clin. Cancer Res. 2013; 19(8):2240-2247.
64. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. Clin. Cancer Res. 2012; 18(5):1472-1482.
65. Weickhardt AJ, Scheier B, Burke JM et al. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer. J. Thorac. Oncol. 2012; 7(12):1807-1814.
66. Oxnard GR, Binder A, Jänne PA. New Targetable Oncogenes in Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2013; 31(8):1097-1104.
67. Planchard D, Mazieres J, Riely GJ et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. ASCO Meet. Abstr. 2013; 31(15_suppl):8009.
68. Mazieres J, Peters S, Cortot A et al. Lung cancer harboring HER2 mutation: epidemiological characteristics and therapeutic perspectives. Ann Oncol 2012:ix403.